Table 2. Clinico-pathological variables related to KRAS gene expression analysed by qPCR for 161 patients.
| Variable | High expression, n (%) | Low expression, n (%) | P -value |
|---|---|---|---|
| Age | |||
| ⩽66 | 20 (21.5) | 74 (78.5) | 0.2 |
| >66 | 21 (31.3) | 46 (68.7) | |
| BMI a | |||
| ⩽25 | 14 (25.5) | 41 (74.5) | 0.7 |
| >25 | 27 (28.1) | 69 (71.9) | |
| FIGO stage b | |||
| I–II | 28 (21.9) | 100 (78.1) | 0.04 |
| III–IV | 13 (39.4) | 20 (60.6) | |
| Histological type | |||
| Endometroid | 25 (18.9) | 107 (81.1) | <0.001 |
| Non-endometroid | 16 (55.2) | 13 (44.8) | |
| Grade c | |||
| Low-medium | 17 (16) | 89 (84) | <0.001 |
| High | 24 (44.4) | 30 (55.6) | |
| Lymph node d | |||
| Negative | 28 (22.2) | 98 (78.8) | 0.02 |
| Positive | 10 (52.6) | 9 (47.4) | |
| Ploidy e | |||
| Diploid | 19 (19) | 80 (81) | 0.001 |
| Aneuploid | 18 (50) | 18 (50) | |
| ERα f | |||
| Positive | 21 (17) | 101 (83) | <0.001 |
| Negative | 19 (53) | 17 (47) | |
| PR g | |||
| Positive | 20 (16) | 104 (84) | <0.001 |
| Negative | 19 (56) | 15 (44) | |
| PIK3CA mut h | |||
| N.m.d | 33 (25.6) | 96 (74.4) | 0.47 |
| Mutated | 6 (28.6) | 15 (78.4) | |
| P53 i | |||
| High | 20 (57.1) | 15 (42.9) | <0.001 |
| Low | 17 (16.5) | 86 (83.5) | |
Abbreviations: BMI=body mass index; ER=oestrogen receptor; FIGO=International Federation of Gynaecology and Obstetrics; KRAS=Homo sapiens v-Ki-ras2 Kirsten rat sarcoma viral oncogenes homologue; N.m.d=no mutations detected; PR=progesterone receptor.
The P-value was based on the χ2-test or Fisher’s exact test as indicated.
Data missing: a10, c1, d16, e26, f3, g3, h11, i23.
b
FIGO 2009 criteria.